Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Risk of secondary tumours in patients with non-metastatic and metastatic human retinoblastoma

Eye volume 37, pages 2327–2334 (2023)Cite this article

Subjects

Abstract

Background

Retinoblastoma is an intraocular cancer in children and infants. Despite all the available treatment options and high survival rates in children with retinoblastoma, exposure to secondary tumours in adulthood is one of the concerns that physicians face. In many cases, dysfunction of the RB1 gene is the main cause of secondary tumours due to retinoblastoma. Therefore, the aim of this study was to evaluate the incidence of other secondary tumours in children with retinoblastoma.

Methods

In this regard, we performed continuous and integrated bioinformatics analyses to find genes, protein products, and signal pathways involved in other cancers.

Results

1170 high-expression genes and 960 low-expression genes between non-invasive and invasive retinoblastoma were isolated. After examining the signal pathways, we observed bladder cancer and small cell lung cancer in the overexpressed genes. We also observed 5 cancers of endometriosis, prostate, non-small cell lung cancer, glioblastoma and renal cell carcinoma in low-expression genes. Based on the P-value index, non-small cell lung cancer, prostate and bladder cancers had the highest risk, and endometriosis cancer showed a lower probability of developing a secondary tumour in patients with retinoblastoma. In addition, the network between proteins also showed us that TP53, CDK2, SRC, MAPK1 proteins with high expression and JUN, HSP90AA1, and UBC proteins with low-expression play a significant role in candidate cancers.

Conclusion

Lastly, we used continuous bioinformatics analysis to show that seven cancers are strongly linked to retinoblastoma cancer. Of course, more research is needed to find the best way to care for children who have been treated for retinoblastoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Molecular function analysis in retinoblastoma.
Fig. 2: Proteins interaction in retinoblastoma hub genes.
Fig. 3: Retinoblastoma secondary tumors gene expression.
Fig. 4: Retinoblastoma secondary tumors candidates in overall view.

Similar content being viewed by others

Data availability

All data generated or analysed during this study are included in this published article.

References

  1. Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: A 2020 review. Indian J Ophthalmol. 2020;68:2356.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kaewkhaw R, Rojanaporn D. Retinoblastoma: etiology, modeling, and treatment. Cancers (Basel). 2020;12:2304.

    Article  CAS  PubMed  Google Scholar 

  3. Soliman S, Kletke S, Roelofs K, VandenHoven C, Mckeen L, Gallie B. Precision laser therapy for retinoblastoma. Expert Rev Ophthalmol. 2018;13:149–59.

    Article  CAS  Google Scholar 

  4. Vempuluru VS, Jakati S, Kaliki S. Delayed metastasis in patients with intraocular retinoblastoma: A review of three cases. Eur J Ophthalmol. 2021;31:2042–7.

    Article  PubMed  Google Scholar 

  5. Tomar AS, Finger PT, Gallie B, Kivelä TT, Mallipatna A, Zhang C, et al. Global retinoblastoma treatment outcomes: Association with national income level. Ophthalmology. 2021;128:740–53.

    Article  PubMed  Google Scholar 

  6. Shields CL, Lally SE. Retinoblastoma, in: Ocul Oncol, Springer, 2019: pp. 91–99.

  7. Chantada G, Schaiquevich P. Management of retinoblastoma in children: current status, pediatr. Drugs. (2015). https://doi.org/10.1007/s40272-015-0121-9.

  8. Berry JL, Polski A, Cavenee WK, Dryja TP, Murphree AL, Gallie BL. The RB1 story: characterization and cloning of the first tumor suppressor gene. Genes (Basel). 2019;10:879.

    Article  CAS  PubMed  Google Scholar 

  9. Tutunchi S, Akhavan S, Bereimipour A, Hossein Ghaderian SM. Evaluation of important molecular pathways and candidate diagnostic biomarkers of noninvasive to invasive stages in gastric cancer by in silico analysis. J Oncol. 2021;2021:5571413.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Wu D, Rice CM, Wang X. Cancer bioinformatics: A new approach to systems clinical medicine. BMC Bioinformatics. 2012:13:71.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Cao M, Wang S, Zou J, Wang W. Bioinformatics analyses of retinoblastoma reveal the retinoblastoma progression subtypes. Bioinforma GENOMICS. 2020;1:1–17. https://doi.org/10.7717/peerj.8873.

    Article  CAS  Google Scholar 

  12. Zeng Y, He T, Liu J, Li Z, Xie F, Chen C, et al. Bioinformatics analysis of multi-omics data identifying molecular biomarker candidates and epigenetically regulatory targets associated with retinoblastoma. Med (Baltim). 2020;0:234–41.

    Google Scholar 

  13. Huang J, Zhang L, Li Z, Lu X. Screening and identification of key biomarkers for retinoblastoma. Medicine (Baltimore). 2020;99:e19952.

    Article  PubMed  Google Scholar 

  14. Cho SJ, Kim JH, Baik SH, Sunwoo L, Bae YJ, Choi BS. Diagnostic performance of MRI of post-laminar optic nerve invasion detection in retinoblastoma: A systematic review and meta-analysis. Neuroradiology. 2021;63:499–509.

    Article  PubMed  Google Scholar 

  15. Gerrish A, Stone E, Clokie S, Ainsworth JR, Jenkinson H, McCalla M, et al. Non-invasive diagnosis of retinoblastoma using cell-free DNA from aqueous humour. Br J Ophthalmol. 2019;103:721–4.

    Article  PubMed  Google Scholar 

  16. Patel S, Vogel J, Bradley K, Chuba PJ, Buchsbaum J, Krasin MJ. Rare tumors: Retinoblastoma, nasopharyngeal cancer, and adrenocorticoid tumors. Pediatr Blood\Cancer. 2021;68:e28253.

    PubMed  Google Scholar 

  17. Alzahem T, Alsarhani W, Albahlal A, Safieh LA, Aldahmash S. History and genetics of retinoblastoma, in: Retin. Present Futur., IntechOpen, 2019.

  18. Woo KI, Harbour JW. Review of 676 second primary tumors in patients with retinoblastoma: association between age at onset and tumor type. Arch Ophthalmol. 2010;128:865–70.

    Article  PubMed  Google Scholar 

  19. Ketteler P, Hülsenbeck I, Frank M, Schmidt B, Jöckel K-H, Lohmann DR. The impact of RB1 genotype on incidence of second tumours in heritable retinoblastoma. Eur J Cancer. 2020;133:47–55.

    Article  CAS  PubMed  Google Scholar 

  20. Zuehlke AD, Beebe K, Neckers L, Prince T. Regulation and function of the human HSP90AA1 gene. Gene. 2015;570:8–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Xiao X, Wang W, Li Y, Yang D, Li X, Shen C, et al. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma. J Exp \ Clin Cancer Res. 2018;37:1–13.

    Google Scholar 

  22. Xiao X, Wang W, Li X, Li Y, Yang D, Shen C, et al., MicroRNA-495 suppresses osteosarcoma invasion and migration by targeting HSP90AA1. Oncotarget. 2018;5.

  23. Dong Z, Yang P, Qiu X, Liang S, Guan B, Yang H, et al. KCNQ1OT1 facilitates progression of non-small-cell lung carcinoma via modulating miRNA-27b-3p/HSP90AA1 axis. J Cell Physiol. 2019;234:11304–14.

    Article  CAS  PubMed  Google Scholar 

  24. Young M-J, Hsu K-C, Lin TE, Chang W-C, Hung J-J. The role of ubiquitin-specific peptidases in cancer progression. J Biomed Sci. 2019;26:1–14.

    Article  Google Scholar 

  25. Chen X, Dou QP, Liu J, Tang D. Targeting ubiquitin—proteasome system with copper complexes for cancer therapy. Front Mol Biosci. 2021;8:116.

    Google Scholar 

  26. Chen X, Chen S, Jiang Z, Gong Q, Tang D, Luo Q, et al. Ubiquitination-related miRNA—mRNA interaction is a potential mechanism in the progression of retinoblastoma. Investig Ophthalmol\Vis Sci. 2021;62:3.

    Article  CAS  Google Scholar 

  27. del Mar Maldonado M, Dharmawardhane S. Targeting rac and Cdc42 GTPases in cancer. Cancer Res. 2018;78:3101–11.

    Article  PubMed Central  Google Scholar 

  28. Chernichenko N, Omelchenko T, Deborde S, Bakst RL, He S, Chen C-H, et al. Cdc42 mediates cancer cell chemotaxis in perineural invasion. Mol Cancer Res. 2020;18:913–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. Targeting STAT3 in cancer immunotherapy. Mol Cancer. 2020;19:1–19.

    Article  Google Scholar 

  30. Gharibi T, Babaloo Z, Hosseini A, Abdollahpour-Alitappeh M, Hashemi V, Marofi F, et al. Targeting STAT3 in cancer and autoimmune diseases. Eur J Pharmacol. 2020;878:173107.

    Article  CAS  PubMed  Google Scholar 

  31. Liu S, Zhang X, Hu C, Wang Y, Xu C. miR-29a inhibits human retinoblastoma progression by targeting STAT3 Corrigendum in/10.3892/or. 2021.8126. Oncol Rep. 2018;39:739–46.

    CAS  PubMed  Google Scholar 

  32. Wang L, Zhang Y, Xin X. Long non-coding RNA MALAT1 aggravates human retinoblastoma by sponging miR-20b-5p to upregulate STAT3. Pathol Pract. 2020;216:152977.

    Article  CAS  Google Scholar 

  33. Ono M, Takeshima M, Nishi A, Higuchi T, Nakano S. Genistein suppresses v-Src-driven proliferative activity by arresting the cell-cycle at G2/M through increasing p21 level in Src-activated human gallbladder carcinoma cells. Nutr Cancer. 2021;73:1471–9.

    Article  CAS  PubMed  Google Scholar 

  34. Liu H, Bi J, Dong W, Yang M, Shi J, Jiang N, et al. Invasion-related circular RNA circFNDC3B inhibits bladder cancer progression through the miR-1178-3p/G3BP2/SRC/FAK axis. Mol Cancer. 2018;17:1–19.

    Article  Google Scholar 

  35. Li M-Y, Peng W-H, Wu C-H, Chang Y-M, Lin Y-L, Chang G-D, et al. PTPN3 suppresses lung cancer cell invasiveness by counteracting Src-mediated DAAM1 activation and actin polymerization. Oncogene. 2019;38:7002–16.

    Article  CAS  PubMed  Google Scholar 

  36. Watt AC, Cejas P, DeCristo MJ, Metzger-Filho O, Lam EYN, Qiu X, et al. CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nat Cancer. 2021;2:34–48.

    Article  CAS  PubMed  Google Scholar 

  37. Zhang Z, Li J, Ou Y, Yang G, Deng K, Wang Q, et al. CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism. Signal Transduct Target Ther. 2020;5:1–13.

    Google Scholar 

  38. Gener P, Rafael D, Seras-Franzoso J, Perez A, Alamo Pindado L, Casas G, et al. Pivotal role of AKT2 during dynamic phenotypic change of breast cancer stem cells. Cancers (Basel). 2019;11:1058.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Liu T, Zhu J, Du W, Ning W, Zhang Y, Zeng Y, et al. AKT2 drives cancer progression and is negatively modulated by miR-124 in human lung adenocarcinoma. Respir Res. 2020;21:1–15.

    Article  Google Scholar 

  40. Bertacchini J, Mediani L, Beretti F, Guida M, Ghalali A, Brugnoli F, et al. Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit. J Cell Physiol. 2019;234:11188–99.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all colleagues in the core facilities for their support.

Author information

Author notes

  1. These authors contributed equally: Reza Sadeghi, Ahmad Bereimipour.

Authors and Affiliations

  1. School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran

    Reza Sadeghi

  2. Medical Genomics Research Center, Tehran Medical Sciences Islamic Azad University, Tehran, Iran

    Hanieh Pirankuraim & Maryam Arabi

  3. Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran

    Shamim Taghvaei Javanshir, Maryam Arabi, Hamid Taghvaei Javanshir & Habibollah Mahmoodzadeh

  4. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran

    Ahmad Bereimipour

  5. Breast Disease Research Center (BDRC), Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

    Habibollah Mahmoodzadeh

  6. International Center for Personalized Medicine (P7MEDICINE), 40235, Düsseldorf, Germany

    Karim Nayernia

Authors
  1. Reza Sadeghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanieh Pirankuraim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shamim Taghvaei Javanshir
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maryam Arabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ahmad Bereimipour
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hamid Taghvaei Javanshir
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Habibollah Mahmoodzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Karim Nayernia
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors Participated in study design, data collection and evaluation, drafting and statistical analysis; Contributed extensively in interpretation of the data and the conclusion and figure design. All authors performed editing and approving the final version of this paper for submission, also participated in the finalisation of the manuscript and approved the final draft.

Corresponding author

Correspondence to Habibollah Mahmoodzadeh.

Ethics declarations

Competing interests

This study was supported by a part of grant of Tehran University of medical science [Projects Code: 99-1-115-47842; 1400-2-259-54530].

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sadeghi, R., Pirankuraim, H., Javanshir, S.T. et al. Risk of secondary tumours in patients with non-metastatic and metastatic human retinoblastoma. Eye 37, 2327–2334 (2023). https://doi.org/10.1038/s41433-022-02345-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41433-022-02345-3

Search

Advanced search

Quick links